ArticlePloS one2026
FAERS-based pharmacovigilance and network toxicology analysis of esomeprazole-associated osteoporosis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis (OP) is a progressive skeletal disorder often exacerbated by pharmacological agents. Proton pump inhibitors (PPIs), particularly esomeprazole, have been epidemiologically linked to OP, but the underlying mechanisms remain unclear.
methodsThis study mined over 55 million adverse event (AE) records from the FDA Adverse Event Reporting System (FAERS) between 2004 and 2024 to identify drug-related OP signals. Four statistical algorithms (ROR, PRR, BCPNN, EBGM) were applied for signal detection. Logistic regression was used to assess independent risk factors. Esomeprazole, the most frequently reported PPI, was further investigated using a network toxicology framework. Drug-target predictions, differential gene expression analysis, protein-protein interaction network construction, molecular docking and molecular dynamics (MD) simulations were conducted to explore potential molecular hypotheses.
resultsA total of 52 drugs showed potential OP-related reporting signals. Among PPI-associated OP-related reports, esomeprazole accounted for the largest proportion and was the only PPI with positive signals across all four algorithms. Logistic regression showed that esomeprazole, age, sex, and low body weight were associated with OP-related adverse event reporting. Time-to-onset analysis showed a median latency of 3.5 years. Network toxicology analysis identified 26 overlapping candidate genes between predicted esomeprazole targets and OP-related DEGs. GO and KEGG analyses highlighted bone-related pathways, including MAPK, Notch, and PI3K/AKT signaling. Protein-protein interaction network analysis identified CXCR4, AKT1, and CASP3 as candidate hub genes. Molecular docking and 100-ns MD simulations supported the binding plausibility and conformational stability of the predicted esomeprazole-target complexes.
conclusionThis pharmacovigilance and computational toxicology study suggests a notable association between esomeprazole and PPI-associated OP-related adverse event reporting. The identified targets and pathways, including CXCR4, AKT1, and CASP3, provide exploratory mechanistic clues and hypothesis-generating evidence. These findings may support individualized bone health risk assessment in long-term PPI users and provide a basis for future validation studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.